Evommune develops novel therapeutics targeting the root causes of chronic inflammatory diseases, utilizing specific antagonists like MRGPRX2 to halt disease progression and alleviate symptoms. The company aims to improve patient outcomes by advancing a clinical-stage pipeline that addresses the debilitating effects of chronic inflammation.
Funding
$115M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
SAFounders
Product
Problem
Chronic inflammatory diseases significantly diminish quality of life. Current treatments often fail to address the underlying causes of inflammation, providing only symptomatic relief.
Solution
Evommune is developing targeted therapeutics designed to halt the progression of chronic inflammatory diseases by addressing their root causes. Their approach involves utilizing specific antagonists, such as MRGPRX2 antagonists, to modulate inflammatory pathways. The company's clinical-stage pipeline aims to provide disease-modifying treatments that improve patient outcomes by targeting the source of chronic inflammation.
Target Audience
The primary target audience includes individuals suffering from chronic inflammatory diseases and the healthcare providers who treat them.
Features
- Development of novel therapies targeting the root causes of chronic inflammatory diseases.
- Focus on specific antagonists like MRGPRX2 to halt disease progression.
- Clinical-stage pipeline addressing the debilitating effects of chronic inflammation.
- Oral MRGPRX2 antagonist (EVO756) in Phase 2 trial for Chronic Inducible Urticaria.